Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
about
Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinomaHigh-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype.Trial Watch: Radioimmunotherapy for oncological indications.Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer.
P2860
Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Concurrent hyperfractionated a ...... a prospective phase II trial.
@ast
Concurrent hyperfractionated a ...... a prospective phase II trial.
@en
type
label
Concurrent hyperfractionated a ...... a prospective phase II trial.
@ast
Concurrent hyperfractionated a ...... a prospective phase II trial.
@en
prefLabel
Concurrent hyperfractionated a ...... a prospective phase II trial.
@ast
Concurrent hyperfractionated a ...... a prospective phase II trial.
@en
P2093
P2860
P1476
Concurrent hyperfractionated a ...... a prospective phase II trial.
@en
P2093
C Stromberger
E-T Becker
H Badakhshi
K-D Wernecke
P2860
P2888
P304
P356
10.1007/S00066-013-0481-4
P577
2013-12-11T00:00:00Z
P6179
1053648090